Towards Identifying an Optimal Time for Amyloid Assessment with Donanemab Treatment (S23.004)
Elucidate the optimal timing for assessing a patient’s amyloid level in response to donanemab treatment through the use of real-world data.
Authors
- Erin Doty (ORCID: https://orcid.org/0000-0003-1400-4427)
- Ivelina Gueorguieva (ORCID: https://orcid.org/0000-0001-5864-8924)
- Sergey Shcherbinin
- Emily C. Collins
- Jared R. Brosch (ORCID: https://orcid.org/0000-0002-6578-0584)
- Mark A. Mintun
- Ming Lu (ORCID: https://orcid.org/0000-0002-7946-9797)
- John Randall Sims (ORCID: https://orcid.org/0009-0009-5090-7886)
- Kay Hoong Chow
Institutions
- Indiana University Health (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212009
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00